Hey narmac I always enjoy your insights. At this stage it is all water under the bridge. The only thing that counts now is Nov 16th and, for me, the primary point of success will be high stat significance in a pre-specified sub group of significant market size or severity of disease. If that does not happen I believe there will be an exciting, fruitfull and long (somewhat shorter because issues like dosage tolerance existing knowledge seem resolved i.e. might start new trials at stage 3?) set of new trials. Or maybe they will move to a more potent version of apabetalone.

Question for all. Don pointed out he believes they have a drug capable for long term chronic use. Again, revealing my scientific ignorance, is there any evidence that apabetalone might achieve reduced 3 pt MACE at higher dosages using a phased/intermittent dosage plan???

Just a thought.

GLTA - we need it. Onward we march.

Toinv